Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Canadeo A, Giever E, Szabo A, Jin Y, Winer E, Badar T, Campos J, Lin C, Anderson C, Shallis R, Muradashvili T, Coltoff A, Guo Q, Patel A, Goldberg L, Abaza Y, Fariduddin M, Ayoub R, Foucar C, Nai N, Kota V, Dalgetty M, Gold M, Guduru M, Atallah E. Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium. Blood 2024, 144: 5174-5174. DOI: 10.1182/blood-2024-198914.Peer-Reviewed Original ResearchWhite blood cell countAcute promyelocytic leukemiaIncidence of relapseHigh-risk diseaseAll-trans retinoic acidOverall survivalDifferentiation syndromeHigh riskArsenic trioxideInduction regimenTreatment regimensSupportive care strategiesCardiovascular comorbiditiesMedian white blood cell countData collection formDoses of gemtuzumab ozogamicinIncidence of CNS relapseIncidence of differentiation syndromeLow incidence of relapseOutcome of APL patientsSuspected acute promyelocytic leukemiaCumulative incidence of relapseDiagnosis of acute promyelocytic leukemiaLow-risk acute promyelocytic leukemiaMortality rateThe Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shah K, El Kettani M, Narra R, Mims A, Coltoff A, Medawar G, Hisrich B, Shallis R, Hunter C, Kota V, Othman T, Jonas B, Desai S, Sacchi de Camargo Correia G, Patel A, Duvall A, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 4184-4184. DOI: 10.1182/blood-2024-205812.Peer-Reviewed Original ResearchCNS relapseCentral nervous system involvementPh+ acute lymphoblastic leukemiaRelapse free survivalTyrosine kinase inhibitorsAcute lymphoblastic leukemiaIncidence of CNS relapseMedian relapse free survivalCentral nervous systemCNS diseaseOverall survivalAllo-HCTIntrathecal chemotherapyWhite blood cellsIntensive chemotherapyPost-relapseT315I mutationBaseline characteristicsMedian time to CNS relapseAllogeneic stem cell transplantationAssociated with significant toxicityIncidence of CNS diseaseMedian white blood cellAdequate CNS prophylaxisCentral nervous system penetration